Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price
New Delhi: Switzerland-based multinational Novartis and US-based Eli Lilly and Company have vehemently opposed any move to issue compulsory licences that would allow generic versions of their critical breast cancer drugs to be made…
Read More...
Read More...